Sol-Gel Technologies's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Sol-Gel Technologies's 5-Year Yield-on-Cost % or its related term are showing as below:
SLGL's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.75 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sol-Gel Technologies 5-Year Yield-on-Cost % Related Terms
SLGL vs AVXL, FATE, FHTX: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sol-Gel Technologies (SLGL) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sol-Gel Technologies and its competitors. According to the industry distribution chart, Sol-Gel Technologies ranks #999999 out of 153 companies in the Biotechnology industry.
Is Sol-Gel Technologies' 5-Year Yield-on-Cost % too high?
Sol-Gel Technologies' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Sol-Gel Technologies ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sol-Gel Technologies has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' 5-Year Yield-on-Cost % compare to AVXL and FATE?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Sol-Gel Technologies in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.75, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $65.57, compared to a current price of $74.50 — trading 13.6% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Sol-Gel Technologies' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $74.50 is trading 13.6% above its estimated GF Value™ of $65.57.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
5-Year Yield-on-Cost %: 0.00
GF Value™: $65.57 vs. price of $74.50 (13.6% above fair value)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
56GF Score
Get the complete analysis for SLGL
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 